NCT02454959 - Crossover Study to Assess the Efficacy of PT003 With and Without a Valved Holding Chamber in Subjects With Moderate to Severe COPD | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 1, 2015

Primary Completion Date

March 25, 2016

Study Completion Date

March 25, 2016

Conditions

COPD

Interventions

DEVICE

GFF MDI (PT003) with Aerochamber

Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) with Aerochamber Plus Valved Holding Chamber

DEVICE

GFF MDI (PT003) without Aerochamber

Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) without Aerochamber Plus Valved Holding Chamber

Trial Locations (6)

Unknown

Pearl Investigative Site, Clearwater

Pearl Investigative Site, Tampa

Pearl Investigative Site, Winter Park

Pearl Investigative Site, Charlotte

Pearl Investigative Site, Winston-Salem

Pearl Investigative Site, Gaffney